JPM2026｜诺和诺德：渴求多元化创新，重点关注中国市场

医药魔方01-14

在JPM2026大会的200余场洽谈中，诺和诺德正在评估各类生物技术创新项目，以寻找到优质标的。经历了一年的重大变革后，诺和诺德的研发负责人透露，虽然诺和诺德在寻求新创新的过程中热衷于并购交易，不过仍将主要精力聚焦于代谢领域的核心业务。去年肥胖症治疗市场格局剧变，诺和诺德随之启动大规模重组计划：不仅更换了首席执行官、宣布大幅裁员，还终止了肝病、肿瘤及干细胞领域的多项早期研发项目。此次重组中，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603065025?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 10:24","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603065025","market":"us","top_or_hot":-1,"title":"JPM2026｜诺和诺德：渴求多元化创新，重点关注中国市场","media":"医药魔方","content":"<div>\n<p>在JPM2026大会的200余场洽谈中，诺和诺德正在评估各类生物技术创新项目，以寻找到优质标的。经历了一年的重大变革后，诺和诺德的研发负责人透露，虽然诺和诺德在寻求新创新的过程中热衷于并购交易，不过仍将主要精力聚焦于代谢领域的核心业务。去年肥胖症治疗市场格局剧变，诺和诺德随之启动大规模重组计划：不仅更换了首席执行官、宣布大幅裁员，还终止了肝病、肿瘤及干细胞领域的多项早期研发项目。此次重组中，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114103934a7181172&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPM2026｜诺和诺德：渴求多元化创新，重点关注中国市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPM2026｜诺和诺德：渴求多元化创新，重点关注中国市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 10:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114103934a7181172&s=b><strong>医药魔方</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在JPM2026大会的200余场洽谈中，诺和诺德正在评估各类生物技术创新项目，以寻找到优质标的。经历了一年的重大变革后，诺和诺德的研发负责人透露，虽然诺和诺德在寻求新创新的过程中热衷于并购交易，不过仍将主要精力聚焦于代谢领域的核心业务。去年肥胖症治疗市场格局剧变，诺和诺德随之启动大规模重组计划：不仅更换了首席执行官、宣布大幅裁员，还终止了肝病、肿瘤及干细胞领域的多项早期研发项目。此次重组中，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114103934a7181172&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4614","symbol_name":"Manus概念股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114103934a7181172&s=b","article_id":"2603065025","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114103934a7181172&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603065025","pubTimestamp":1768357486,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在JPM2026大会的200余场洽谈中，诺和诺德正在评估各类生物技术创新项目，以寻找到优质标的。目前，诺和诺德一方面持续强化肥胖症治疗领域的产品布局，另一方面积极探索代谢性疾病相关的其他适应症。Lange透露，诺和诺德深度参与本届摩根大通医疗健康大会上安排的超200场会议，旨在挖掘新的候选药物，甚至收购完整的技术平台。为网罗这些多元化的创新项目，诺和诺德采取开放态度，并不限定创新技术的来源，中国自然是重点关注的市场之一。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4614":"Manus概念股","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","FXI":"中国大盘股ETF-iShares","BK4007":"制药","MCHI":"中国ETF-iShares MSCI","NVO":"诺和诺德","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","ASHR":"德银沪深300指数ETF","DRAG":"中国龙ETF-Roundhill","ASHS":"德银沪深中证500指数ETF","CQQQ":"中国科技指数ETF-Guggenheim","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","CWEB":"两倍做多沪深中国互联网股票ETF-Direxion","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","KWEB":"中国海外互联网ETF-KraneShares","CHAU":"2倍做多沪深300ETF-Direxion"},"translate_title":"JPM2026 | Novo Nordisk: Eager for diversified innovation, focusing on the Chinese market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CQQQ":0.6,"ASHR":0.6,"CHAU":0.6,"ASHS":0.6,"NVO":1.97,"MCHI":0.6,"FXI":0.6,"DRAG":0.6,"KWEB":0.6,"CWEB":0.6},"content_text":"在JPM2026大会的200余场洽谈中，诺和诺德正在评估各类生物技术创新项目，以寻找到优质标的。经历了一年的重大变革后，诺和诺德的研发负责人透露，虽然诺和诺德在寻求新创新的过程中热衷于并购交易，不过仍将主要精力聚焦于代谢领域的核心业务。去年肥胖症治疗市场格局剧变，诺和诺德随之启动大规模重组计划：不仅更换了首席执行官、宣布大幅裁员，还终止了肝病、肿瘤及干细胞领域的多项早期研发项目。此次重组中，医学博士Martin Holst Lange升任首席科学官。“一直以来，我们都是一家业务相对集中、目标明确的公司，”他表示，“自百年前成立之初，我们便深耕糖尿病领域。”依托糖尿病领域的技术积淀，诺和诺德打造出以“司美格鲁肽”为核心的减肥产品矩阵。目前，诺和诺德一方面持续强化肥胖症治疗领域的产品布局，另一方面积极探索代谢性疾病相关的其他适应症。就在上个月，司美格鲁肽迎来重要突破——击败竞争对手礼来制药，成为首款获得FDA批准的口服GLP-1类减肥药。在新任首席执行官Maziar Mike Doustdar的领导下，诺和诺德毫不讳言其充实肥胖症治疗管线的战略目标。去年秋季，诺和诺德曾竞购Metsera Therapeutics，试图将其从辉瑞手中争取过来，不过最终未能如愿。Lange透露，诺和诺德深度参与本届摩根大通医疗健康大会上安排的超200场会议，旨在挖掘新的候选药物，甚至收购完整的技术平台。“这些项目覆盖范围极广，既有早期研究，也有后期临床试验阶段的成果；规模有大有小，创新方向更是各具特色。”他解释道，“运气好的话——比如今天我就有好几次这样的机会——你能从不同的项目中获得灵感，将这些闪光点整合起来，最终创造出更具协同价值的成果。”为网罗这些多元化的创新项目，诺和诺德采取开放态度，并不限定创新技术的来源，中国自然是重点关注的市场之一。Lange也指出，日本、德国等其他亚欧国家的创新潜力正日益凸显，成为愈发具有吸引力的合作选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603065025","isCrawlerRequest":true}